Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Makoto Endo"'
Autor:
Takeshi Hirose, Shinji Kohsaka, Hiroyuki Mano, Masachika Ikegami, Yoshihiro Matsumoto, Yasuharu Nakashima, Makoto Endo
Publikováno v:
Lung Cancer. 152:135-142
Objectives Exon 20 insertion mutations of epidermal growth factor receptor (EGFR) have been identified as oncogenic mutations in general; however, the functional relevance of each remains largely uninvestigated. Herein, we comprehensively assessed th
Autor:
Hiroaki Hiraga, Makoto Endo, Takafumi Ueda, Akihiko Matsumine, Toru Hiruma, Nobuhito Araki, Hideo Morioka, Tsukasa Yonemoto, Toshiyuki Kunisada, Kazato Goda, Shunji Takahashi, Akira Kawai, Hideshi Sugiura, Mitsuru Takahashi
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3656-3667 (2020)
Cancer Medicine
Cancer Medicine
The time course of the response to each drug is important to avoid inappropriate termination of treatment by misjudging tumor progression; however, little is known about soft tissue sarcoma (STS) regarding this matter. This study aimed to perform a t
Autor:
Yoshihiro Matsumoto, Hitoshi Kusaba, Hiroshi Ariyama, Ryuji Yasumatsu, Eishi Baba, Junji Kishimoto, Makoto Endo, Shohei Moriyama, Toshifumi Fujiwara, Nokitaka Setsu, Koichi Akashi, Takahiro Wakasaki, Kenji Tsuchihashi, Kenta Nio, Yasuharu Nakashima, Mitsuhiro Fukata, Kyoko Yamaguchi, Mamoru Ito, Tomoyasu Yoshihiro, Keisuke Taguchi
Publikováno v:
International Journal of Surgery Oncology. 5:e891-e896
Tyrosine kinase inhibitors (TKI) work against various types of cancer by inhibiting angiogenic signaling. Little is understood about the incidence, characteristics, and risk factors associated with thromboembolism induced by TKI in routine clinical p
Autor:
Yoshihiro Matsumoto, Yu Toda, Nokitaka Setsu, Kenichiro Yahiro, Suguru Fukushima, Tomoya Matsunobu, Atsushi Kimura, Makoto Endo, Hidetaka Yamamoto, Makoto Nakagawa, Yoshinao Oda, Toshifumi Fujiwara, Eijiro Shimada, Masaya Kanahori, Yasuharu Nakashima
BackgroundDenosumab is a game-changing drug for giant cell tumor of bone (GCTB); however, its clinical biomarker in terms of post-administration ossification of the tumors has not been elucidated. The aims of this study were to investigate the relati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45409477904fc059535cebe4d1bf0eac
https://doi.org/10.21203/rs.3.rs-738278/v1
https://doi.org/10.21203/rs.3.rs-738278/v1
Autor:
Yoshihiro Matsumoto, Hiroshi Ariyama, Makoto Endo, Tomoyasu Yoshihiro, Koichi Akashi, Hirofumi Ohmura, Kohei Arimizu, Eishi Baba, Kyoko Yamaguchi, Mamoru Ito, Fumiyasu Hanamura, Nokitaka Setsu, Kenro Tanoue, Takashi Imajima, Yudai Shinohara, Yasuharu Nakashima, Satoru Yamaga, Taichi Isobe, Toshifumi Fujiwara, Hitoshi Kusaba, Kenji Tsuchihashi
Publikováno v:
Scientific Reports
Doxorubicin is a first-line therapy for patients with unresectable advanced soft tissue sarcoma (STS). However, because of cardiotoxicities, it is not used for patients with cardiac problems. Eribulin has exhibited efficacy for advanced STS in second
Autor:
Yoshihiro Matsumoto, Hiroshi Ariyama, Taichi Isobe, Akira Maekawa, Yukihide Iwamoto, Keiichiro Iida, Makoto Nakagawa, Yoshinao Oda, Tomoya Nawata, Ryunosuke Oyama, Nokitaka Setsu, Akira Nabeshima, Kenji Tsuchihashi, Makoto Endo, Eishi Baba, Kenichi Kohashi, Takeshi Hirose, Hitoshi Kusaba, Hidetaka Yamamoto, Tomoya Matsunobu, Eijiro Shimada, Masaya Kanahori, Toshifumi Fujiwara, Yasuharu Nakashima, Mamoru Ito, Koichi Akashi
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 4972, p 4972 (2021)
Volume 10
Issue 21
Journal of Clinical Medicine, Vol 10, Iss 4972, p 4972 (2021)
Volume 10
Issue 21
Pazopanib, trabectedin, and eribulin are administered for the treatment of soft tissue sarcomas (STSs)
however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral
however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral
Autor:
Shintaro Iwata, Yoshihiro Matsumoto, Makoto Endo, Satoshi Takenaka, Toru Akiyama, Hiroyuki Kawashima, Munenori Watanuki, Hiroyuki Tsuchiya, Hirohisa Katagiri, Tsukasa Yonemoto, Hiroaki Hiraga, Satoshi Tsukushi, Robert Nakayama, Haruhiko Fukuda, Tomoko Kataoka, Ryunosuke Machida, Toshifumi Ozaki, Kazuhiro Tanaka, Keisuke Ae, Akihito Nagano
Publikováno v:
Journal of Clinical Oncology. 39:TPS11580-TPS11580
TPS11580 Background: Soft tissue sarcomas (STS) are a rare type of malignancy, which comprises of a variety of histologies. Chemotherapy is the standard treatment for patients with advanced STS. Doxorubicin alone or in combination with ifosfamide is
Autor:
Fusako Kito, Makoto Endo, Tadashi Kondo, Rieko Oyama, Mami Takahashi, Marimu Sakumoto, Akihiko Yoshida, Zhiwei Qiao, Yoko Takai, Akira Kawai, Kumiko Shiozawa
Publikováno v:
Japanese Journal of Clinical Oncology. 47:954-961
Background Leiomyosarcoma (LMS) is one of most aggressive mesenchymal malignancies that differentiate towards smooth muscle. The clinical outcome of LMS patients is poor; as such, there is an urgent need for novel therapeutic approaches. Experimental
Autor:
Makoto Endo, Hiroaki Hiraga, Takafumi Ueda, Robert Nakayama, Naomasa Fukase, Eisuke Kobayashi, Masato Tomita, Akira Kawai, Tomoaki Mori, Hideo Morioka
Publikováno v:
Journal of Surgical Oncology. 114:495-500
Background Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods Forty-eight patients (average age: 5
Autor:
Jun Ichi Fukushi, Yukihide Iwamoto, Nobuhiko Yokoyama, Suguru Fukushima, Makoto Endo, Tomoya Matsunobu, Mihoko Hatano, Seiji Okada, Akira Nabeshima, Yoshihiro Matsumoto
Publikováno v:
Scientific Reports
Synovial sarcoma (SS) is a rare high-grade malignant mesenchymal tumour with a relatively poor prognosis despite intensive multimodal therapy. Although pazopanib, a multi-kinase inhibitor, is often used for advanced SS, most cases eventually become r